HAYWARD, Calif. / May 18, 2023 / Business Wire / Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced nsPFA will be featured in three presentations at the upcoming Heart Rhythm 2023 Annual Meeting in New Orleans, LA from May 19-21.
“We are very encouraged that the preclinical work completed with our nsPFA devices will be featured among leading technologies at the premier meeting of heart rhythm professionals from around the world,” said Kevin Danahy, Chief Executive Officer of Pulse Biosciences. “This data is a validation of the quality of the preclinical work completed with our physician collaborators and our opportunity to advance the treatment of atrial fibrillation. We are excited to continue on the path towards first in-human clinical use.”
Poster Presentations featuring nsPFA
Poster Session IV – Ablation
May 21, 2023, at 9:30-11:30 am CT
About Pulse Biosciences®
Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The Company’s proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its nsPFA technology for use in the treatment of atrial fibrillation as well as a select few other opportunities currently served by alternative established ablation procedures. Visit pulsebiosciences.com to learn more.
Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.
| Last Trade: | US$17.82 |
| Daily Change: | -0.90 -4.81 |
| Daily Volume: | 107,741 |
| Market Cap: | US$1.100B |
January 13, 2025 December 17, 2024 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
